Press release
Malaria Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Malaria Pipeline
Curious about the latest updates in the Malaria Pipeline? Click here to explore the therapies and trials making headlines @ Malaria Pipeline Outlook Report- https://www.delveinsight.com/sample-request/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Malaria Pipeline Report
• On 29 September 2025, GlaxoSmithKline announced a study to evaluate the safety and immunogenicity of reduced antigen doses and alternative vaccination regimes for RTS,S/AS01E in healthy children aged 5-60 months in a malaria-endemic area.
• DelveInsight's Malaria Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Malaria treatment.
• The leading Malaria Companies such as Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen and others.
• Promising Malaria Therapies such as KAE609, Coartem, VMP001, BNT165e, ARTESUNATE + AMODIAQUINE, Chloroquine, MMV390048 40mg, INE963, Verorab Vaccine and others.
Want to know which companies are leading innovation in Malaria? Dive into the full pipeline insights @ Malaria Clinical Trials Assessment- https://www.delveinsight.com/sample-request/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Malaria Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Malaria Pipeline Report also highlights the unmet needs with respect to the Malaria.
Malaria Overview
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable. In 2019, there were an estimated 229 million cases of malaria worldwide. Malaria is caused by Plasmodium parasites. The parasites are spread to people through the bites of infected female Anopheles mosquitoes, called "malaria vectors." There are 5 parasite species that cause malaria in humans, and 2 of these species - P. falciparum and P. vivax - pose the greatest threat.
Malaria Emerging Drugs Profile
• Cipargamin: Novartis
Cipargamin is the first antimalarial drug candidate with a novel mechanism of action to achieve positive clinical proof-of-concept in over 20 years. Cipargamin, the first compound in the spiroindolone class of treatment, works through a novel mechanism of action that involves inhibition of a P-type cation-transporter ATPase4 (PfATP4), which regulates sodium concentration in the parasite. Because Cipargamin also appears to be effective against the sexual forms of the parasite, it could potentially help prevent disease transmission. Cipargamin was tested in adult patients with uncomplicated malaria and showed a median parasite clearance time of 12 hours, including in patients with resistant infections. Currently the product is in Phase II stage of development for the treatment of Malaria.
If you're tracking ongoing Malaria Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Malaria Treatment Drugs- https://www.delveinsight.com/sample-request/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Malaria Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Malaria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malaria Treatment.
• Malaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Malaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malaria market.
Malaria Companies
Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen and others.
Malaria Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal
Malaria Products have been categorized under various Molecule types such as,
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride
From emerging drug candidates to competitive intelligence, the Malaria Pipeline Report covers it all - check it out now @ Malaria Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Malaria Pipeline Report
• Coverage- Global
• Malaria Companies- Sanaria, Novartis, GlaxoSmithKline, Lyndra Therapeutics, Tarsus Pharmaceuticals, GeoVax, Bharat Biotech, Sumitomo Pharma, Zymergen and others.
• Promising Malaria Therapies- KAE609, Coartem, VMP001, BNT165e, ARTESUNATE + AMODIAQUINE, Chloroquine, MMV390048 40mg, INE963, Verorab Vaccine and others.
• Malaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Malaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Malaria Treatment landscape in this detailed analysis @ Malaria Emerging Drugs and Major Players- https://www.delveinsight.com/sample-request/malaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Introduction
2. Executive Summary
3. Malaria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Malaria- DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. PfSPZ Vaccine: Sanaria
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Cipargamin: Novartis
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I/II)
14. Company name: Drug name
15. Drug profiles in the detailed report.....
16. Early Stage Products (Phase I)
17. INE963: Novartis
18. Drug profiles in the detailed report.....
19. Preclinical Stage Products
20. Lotilaner: Tarsus Pharmaceuticals
21. Drug profiles in the detailed report.....
22. Inactive Products
23. Malaria Key Companies
24. Malaria Key Products
25. Malaria- Unmet Needs
26. Malaria- Market Drivers and Barriers
27. Malaria- Future Perspectives and Conclusion
28. Malaria Analyst Views
29. Malaria Key Companies
30. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malaria Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight here
News-ID: 4220871 • Views: …
More Releases from DelveInsight Business Research LLP
Pemphigus Vulgaris Market Size (7MM) is going to be ~USD 360 million in 2025, an …
(Albany, USA) DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Pemphigus Vulgaris Market. Download sample report @ https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Pemphigus Vulgaris Market Report
• Among the 7MM, the United…
Underactive Bladder Therapeutics Market Size in the 7MM is Expected to Grow Majo …
DelveInsight's "Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Underactive Bladder Market. Download sample report @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Underactive Bladder Market Report
• In 2023, the prevalent cases of LUTS…
The Peripheral Nerve Injury Market Size (7MM) was ~USD 2.4 Billion in 2023, it i …
(Albany, USA) DelveInsight's "Peripheral Nerve Injury Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Peripheral Nerve Injury, historical and forecasted epidemiology as well as the Peripheral Nerve Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Explore In-depth insights into the evolving Peripheral Nerve Injury Market. Download sample report @ https://www.delveinsight.com/sample-request/peripheral-nerve-injuries-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Peripheral Nerve Injury…
Acute Lymphocytic Leukemia Market Size (7MM) is going to be ~USD 1,878 Million i …
(Albany, USA) DelveInsight's "Acute Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Acute Lymphocytic Leukemia, historical and forecasted epidemiology as well as the Acute Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Explore In-depth insights into the evolving Acute Lymphocytic Leukemia Market. Download sample report @ https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Acute Lymphocytic…
More Releases for Malaria
Industry Dynamics of Cerebral Malaria Therapeutics
Global Cerebral Malaria Therapeutics Market: Overview
Cerebral malaria, a severe neuropathological complication, primarily caused by Plasmodium falciparum. The infectious disease has become prevalent in tropical and sub-tropical countries. The cerebral malaria therapeutics market has evolved on the back of increased understanding of pathogenesis of the neurological syndrome. A growing array of biomarkers and tool in recent years have helped underpin the growing revenue potential in the market, giving rise to numerous…
Malaria Vaccines – Paving the Way for a Malaria-free World
Recent Study on “Malaria Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis and Forecast, 2018-2026” Added to Coherent Market Insights Reports Database.
Malaria Vaccines Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market. The Malaria Vaccines market research report is a professional…
Malaria Disease Drug Pipeline Analysis
“Malaria Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Malaria. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each drug…
Rising Prevalence of Cerebral Malaria and Increasing Novel Drug Treatment Drives …
Malaria is a mosquito-borne infectious disease affecting humans and animals caused by parasitic protozoan belonging to the plasmodium family. Malaria is typically transmitted from human to human through the bite of an infected Anopheles (female) mosquito. Symptoms of malaria include fever, headache, fatigue, muscle pain, diarrhea, anemia, and vomiting. Severe malaria can cause yellow skin, seizures, coma, or death. Cerebral malaria is a form of severe malaria. Cerebral malaria has…
Rising Prevalence of Cerebral Malaria and Increasing Novel Drug Treatment Drives …
Malaria is a mosquito-borne infectious disease affecting humans and animals caused by parasitic protozoan belonging to the plasmodium family. Malaria is typically transmitted from human to human through the bite of an infected Anopheles (female) mosquito. Symptoms of malaria include fever, headache, fatigue, muscle pain, diarrhea, anemia, and vomiting. Severe malaria can cause yellow skin, seizures, coma, or death. Cerebral malaria is a form of severe malaria. Cerebral malaria has…
Malaria Diagnostics Market : Future Growth Potential Of The Malaria Diagnostic & …
Malaria is caused by the Plasmodium parasite, which is transmitted by the female Anopheles mosquito. As per the WHO, there were around 203 mn cases of malaria worldwide in 2012, resulting in approximately 627,000 deaths. The diagnosis of malaria involves detection with the help of blood tests and microscopy. Early and accurate diagnosis of malaria is vital for the rapid recovery of the patient and this has raised investments in…
